Kawasumi Laboratories, Incorporated Stock

7703

JP3225800006

Medical Equipment, Supplies & Distribution

Latest news : Kawasumi Laboratories, Incorporated

20-09-29	Sumitomo Bakelite Company Limited completed the acquisition of an additional 65.99% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥25.7 billion.	CI
20-07-30	Sumitomo Bakelite Company Limited made an offer to acquire the remaining 76.95% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥27 billion.	CI
20-02-05	Kawasumi Laboratories, Incorporated Reports Consolidated Earnings Results for Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
19-11-07	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 2, 2019; Provides Year End Dividend Guidance for the Year Ending March 31, 2020	CI
19-08-07	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2020 and for the Year Ending March 31, 2020	CI
19-05-15	Sumitomo Bakelite Company Limited completed the acquisition of 20.8% stake in Kawasumi Laboratories, Incorporated.	CI
19-03-19	Sumitomo Bakelite Company Limited executed a capital and business alliance agreement to acquire 20.76% stake in Kawasumi Laboratories, Incorporated.	CI
18-08-09	Tranche Update on Kawasumi Laboratories, Incorporated's Equity Buyback Plan announced on August 9, 2018.	CI
18-08-09	Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million.	CI
18-08-09	Kawasumi Laboratories, Incorporated announces an Equity Buyback for 1,300,000 shares, representing 5.96% for ¥932.1 million.	CI
18-08-08	Kawasumi Laboratories, Incorporated authorizes a Buyback Plan.	CI
18-05-14	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2018; Announces Dividend for the Year Ended March 31, 2018, Payable on June 22, 2018; Provides Earnings Guidance or the Year Ending March 31, 2019; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2019	CI
18-02-07	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2018	CI

More news

Managers and Directors: Kawasumi Laboratories, Incorporated

Manager	Title	Age	Since
Takashi Kobayashi CEO	Chief Executive Officer	63	2021-09-30
Takeshi Saino CEO	Chief Executive Officer	64	-
Shigeharu Ochiai AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Takeshi Saino BRD	Director/Board Member	64	2014-05-31
Takashi Kobayashi CHM	Chairman	63	2021-09-30
Akinori Kanaoka BRD	Director/Board Member	-	-

More insiders

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAWASUMI LABORATORIES, INCORPORATED	-.--%	-.--%	-	-	335M
ABBOTT LABORATORIES	+0.24%	-2.12%	-19.11%	-1.80%	182B
MEDTRONIC PLC	-0.24%	-1.77%	-4.10%	+2.32%	110B
CENCORA, INC.	+3.57%	-0.44%	+8.51%	+71.16%	59.59B
HOYA CORPORATION	-3.24%	+5.37%	+34.48%	+50.33%	55.04B
BECTON, DICKINSON AND COMPANY	+0.32%	+1.34%	-3.52%	-36.98%	46.87B
MEDLINE INC.	-12.79%	-8.52%	-	-	35.55B
DEXCOM, INC.	-4.92%	+10.01%	+9.54%	-31.31%	32.81B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	+4.02%	+46.96%	-6.41%	24.54B
STERIS PLC	-0.06%	-0.90%	+3.95%	+2.96%	22.69B
Average	-1.62%	+1.45%	+9.59%	+6.29%	63.33B
Weighted average by Cap.	-0.92%	+0.22%	-0.27%	+7.65%

See all sector performances

Kawasumi Laboratories, Incorporated is a Japan-based company engaged in the manufacture and sale of medical equipment and products. The Company operates in two business segments. The Blood- and Blood Vessel-related segment is engaged in the manufacture and sale of blood bags, blood collecting kits, blood transfer sets and others. The Extracorporeal Circulation segment mainly provides dialyzers, blood circuits, arterial venous fistula (AVF) needles, blood filters, physiological saline, artificial heart lung circuits and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company